Gilead coronavirus drug | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Wednesday
November 29, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
WEDNESDAY, NOVEMBER 29, 2023

Gilead coronavirus drug

Vials of investigational coronavirus disease (Covid-19) treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, US March 18, 2020. Gilead Sciences Inc/Handout via Reuters
Coronavirus chronicle

US to allow states to distribute Gilead's remdesivir to fight Covid-19

Gilead’s drug has shown promise in helping patients infected with Covid-19, the illness caused by the novel coronavirus, and is being closely watched on how the limited supply is distributed

FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (Covid-19), during the outbreak of the coronavirus disease (Covid-19), in Oceanside, California, US, April 29, 2020. REUTERS/Mike Blake/
Coronavirus chronicle

Will Gilead price its coronavirus drug for public good or company profit?

Photo: Collected
Coronavirus chronicle

Gilead Sciences exporting remdesivir, CEO says

An ampule of Ebola drug remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (Covid-19) continues/ Reuters
Coronavirus chronicle

Explainer: What does new data say about Gilead's experimental coronavirus drug?

An ampule of Ebola drug remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (Covid-19) continues/ Reuters
Coronavirus chronicle

Trial of Gilead's potential coronavirus treatment running ahead of schedule, researcher says

In this photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States.AP Photo
Coronavirus chronicle

1st results in on Gilead coronavirus drug; more study needed

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]